Is CTSO or NRXS more profitable?

Cytosorbents has a net margin of -48.94% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -48.94% -309.53% -40.60% NeurAxis -492.76% N/A -641.25%

Does the media favor CTSO or NRXS?

In the previous week, Cytosorbents had 7 more articles in the media than NeurAxis. MarketBeat recorded 9 mentions for Cytosorbents and 2 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.99 beat Cytosorbents' score of -0.49 indicating that NeurAxis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LUNG or CTSO more profitable?

Cytosorbents has a net margin of -48.94% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -96.66% -38.32% Cytosorbents -48.94% -309.53% -40.60%

Does the media refer more to LUNG or CTSO?

In the previous week, Cytosorbents had 8 more articles in the media than Pulmonx. MarketBeat recorded 9 mentions for Cytosorbents and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.50 beat Cytosorbents' score of -0.49 indicating that Pulmonx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytosorbents 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTSO or NNOX?

In the previous week, Nano-X Imaging had 20 more articles in the media than Cytosorbents. MarketBeat recorded 29 mentions for Nano-X Imaging and 9 mentions for Cytosorbents. Nano-X Imaging's average media sentiment score of 0.05 beat Cytosorbents' score of -0.49 indicating that Nano-X Imaging is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nano-X Imaging 1 Very Positive mention(s) 0 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CTSO or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to Cytosorbents' net margin of -48.94%. LENSAR's return on equity of -183.19% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -48.94% -309.53% -40.60% LENSAR 50.94% -183.19% 42.26%

Does the media refer more to CTSO or LNSR?

In the previous week, Cytosorbents had 8 more articles in the media than LENSAR. MarketBeat recorded 9 mentions for Cytosorbents and 1 mentions for LENSAR. LENSAR's average media sentiment score of 0.00 beat Cytosorbents' score of -0.49 indicating that LENSAR is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CTSO or DXR?

Cytosorbents currently has a consensus target price of $5.38, indicating a potential upside of 1,393.06%. Given Cytosorbents' higher probable upside, equities analysts plainly believe Cytosorbents is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, CTSO or DXR?

Daxor has lower revenue, but higher earnings than Cytosorbents. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytosorbents $37.06M 0.61 -$8.20M -$0.19 N/A Daxor N/A N/A N/A N/A N/A

Is CTSO or DXR more profitable?

Daxor has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. Daxor's return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -48.94% -309.53% -40.60% Daxor N/A N/A N/A

Cytosorbents (CTSO) Competitors

$0.36 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$0.37 +0.01 (+1.67%)

As of 08/7/2026 06:07 PM Eastern

Compare

CTSO vs. NRXS, LUNG, NNOX, LNSR, and DXR

Should you buy Cytosorbents stock or one of its competitors? MarketBeat compares Cytosorbents with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytosorbents include NeurAxis (NRXS), Pulmonx (LUNG), Nano-X Imaging (NNOX), LENSAR (LNSR), and Daxor (DXR). These companies are all part of the "healthcare equipment" industry.

How does Cytosorbents compare to NeurAxis?

Cytosorbents (NASDAQ:CTSO) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Cytosorbents has a net margin of -48.94% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-309.53%	-40.60%
NeurAxis	-492.76%	N/A	-641.25%

Cytosorbents has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Cytosorbents currently has a consensus price target of $5.38, suggesting a potential upside of 1,393.06%. NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 83.36%. Given Cytosorbents' higher probable upside, analysts clearly believe Cytosorbents is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Cytosorbents had 7 more articles in the media than NeurAxis. MarketBeat recorded 9 mentions for Cytosorbents and 2 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.99 beat Cytosorbents' score of -0.49 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 7.8% of Cytosorbents shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A
NeurAxis	$4.28M	20.66	-$14.63M	-$0.81	N/A

Summary

Cytosorbents beats NeurAxis on 9 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Pulmonx has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Pulmonx currently has a consensus target price of $7.67, indicating a potential upside of 275.82%. Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,393.06%. Given Cytosorbents' higher probable upside, analysts clearly believe Cytosorbents is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by insiders. Comparatively, 7.8% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cytosorbents has lower revenue, but higher earnings than Pulmonx. Cytosorbents is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.97	-$54M	-$1.16	N/A
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A

Cytosorbents has a net margin of -48.94% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
Cytosorbents	-48.94%	-309.53%	-40.60%

In the previous week, Cytosorbents had 8 more articles in the media than Pulmonx. MarketBeat recorded 9 mentions for Cytosorbents and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.50 beat Cytosorbents' score of -0.49 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pulmonx and Cytosorbents tied by winning 8 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to Nano-X Imaging?

Cytosorbents (NASDAQ:CTSO) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cytosorbents has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Cytosorbents has a net margin of -48.94% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-309.53%	-40.60%
Nano-X Imaging	-716.44%	-70.96%	-62.26%

Cytosorbents has higher revenue and earnings than Nano-X Imaging. Cytosorbents is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A
Nano-X Imaging	$13.02M	5.67	-$75.02M	-$1.58	N/A

In the previous week, Nano-X Imaging had 20 more articles in the media than Cytosorbents. MarketBeat recorded 29 mentions for Nano-X Imaging and 9 mentions for Cytosorbents. Nano-X Imaging's average media sentiment score of 0.05 beat Cytosorbents' score of -0.49 indicating that Nano-X Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nano-X Imaging	1 Very Positive mention(s)	0 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytosorbents currently has a consensus price target of $5.38, indicating a potential upside of 1,393.06%. Nano-X Imaging has a consensus price target of $4.00, indicating a potential upside of 277.36%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than Nano-X Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.67

Summary

Cytosorbents beats Nano-X Imaging on 9 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to LENSAR?

Cytosorbents (NASDAQ:CTSO) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Cytosorbents currently has a consensus price target of $5.38, suggesting a potential upside of 1,393.06%. LENSAR has a consensus price target of $10.00, suggesting a potential upside of 65.56%. Given Cytosorbents' higher probable upside, equities research analysts plainly believe Cytosorbents is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cytosorbents had 8 more articles in the media than LENSAR. MarketBeat recorded 9 mentions for Cytosorbents and 1 mentions for LENSAR. LENSAR's average media sentiment score of 0.00 beat Cytosorbents' score of -0.49 indicating that LENSAR is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cytosorbents has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, LENSAR has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

LENSAR has a net margin of 50.94% compared to Cytosorbents' net margin of -48.94%. LENSAR's return on equity of -183.19% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-309.53%	-40.60%
LENSAR	50.94%	-183.19%	42.26%

Cytosorbents has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A
LENSAR	$58.44M	1.27	-$34.28M	-$0.58	N/A

Summary

LENSAR beats Cytosorbents on 10 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to Daxor?

Cytosorbents (NASDAQ:CTSO) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Cytosorbents currently has a consensus target price of $5.38, indicating a potential upside of 1,393.06%. Given Cytosorbents' higher probable upside, equities analysts plainly believe Cytosorbents is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 51.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Daxor has lower revenue, but higher earnings than Cytosorbents.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Daxor has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. Daxor's return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-309.53%	-40.60%
Daxor	N/A	N/A	N/A

In the previous week, Cytosorbents had 9 more articles in the media than Daxor. MarketBeat recorded 9 mentions for Cytosorbents and 0 mentions for Daxor. Daxor's average media sentiment score of 0.00 beat Cytosorbents' score of -0.49 indicating that Daxor is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytosorbents	Neutral
Daxor	Neutral

Cytosorbents has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Daxor has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

Daxor beats Cytosorbents on 6 of the 11 factors compared between the two stocks.

Get Cytosorbents News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTSO vs. The Competition

Export

Metric	Cytosorbents	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.62M	$5.76B	$7.00B	$12.99B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-1.24	24.26	270.59	25.05
Price / Sales	0.61	68.36	599.45	84.15
Price / Cash	N/A	33.55	28.89	37.44
Price / Book	4.00	6.11	11.21	6.43
Net Income	-$8.20M	$149.01M	$3.45B	$348.10M
7 Day Performance	-2.20%	2.54%	3.41%	2.68%
1 Month Performance	-5.59%	0.78%	-0.71%	-0.83%
1 Year Performance	-64.00%	4.93%	77.31%	23.97%

Cytosorbents Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTSO Cytosorbents	2.2479 of 5 stars	$0.36 flat	$5.38 +1,393.1%	-64.0%	$22.62M	$37.06M	N/A	220	News Coverage Earnings Report Analyst Revision Gap Up
NRXS NeurAxis	2.0044 of 5 stars	$7.01 +6.4%	$13.00 +85.4%	+188.2%	$87.46M	$4.28M	N/A	19	Upcoming Earnings Gap Up
LUNG Pulmonx	2.821 of 5 stars	$2.06 -2.8%	$7.67 +272.2%	+31.6%	$87.01M	$90.50M	N/A	250	High Trading Volume
NNOX Nano-X Imaging	3.6831 of 5 stars	$1.07 -2.7%	$4.00 +273.8%	-77.2%	$74.47M	$13.02M	N/A	190	Trending News Upcoming Earnings
LNSR LENSAR	1.1132 of 5 stars	$5.58 +3.7%	$10.00 +79.2%	-53.1%	$68.52M	$58.44M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTSO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytosorbents (CTSO) Competitors

CTSO vs. NRXS, LUNG, NNOX, LNSR, and DXR

How does Cytosorbents compare to NeurAxis?

Summary

How does Cytosorbents compare to Pulmonx?

Summary

How does Cytosorbents compare to Nano-X Imaging?

Summary

How does Cytosorbents compare to LENSAR?

Summary

How does Cytosorbents compare to Daxor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytosorbents (CTSO) Competitors

CTSO vs. NRXS, LUNG, NNOX, LNSR, and DXR

How does Cytosorbents compare to NeurAxis?

Is CTSO or NRXS more profitable?

Which has more risk & volatility, CTSO or NRXS?

Do analysts recommend CTSO or NRXS?

Does the media favor CTSO or NRXS?

Do institutionals and insiders hold more shares of CTSO or NRXS?

Which has preferable valuation and earnings, CTSO or NRXS?

Summary

How does Cytosorbents compare to Pulmonx?

Which has more risk and volatility, LUNG or CTSO?

Do analysts prefer LUNG or CTSO?

Do insiders & institutionals believe in LUNG or CTSO?

Which has stronger valuation and earnings, LUNG or CTSO?

Is LUNG or CTSO more profitable?

Does the media refer more to LUNG or CTSO?

Summary

How does Cytosorbents compare to Nano-X Imaging?

Do institutionals and insiders believe in CTSO or NNOX?

Which has more risk and volatility, CTSO or NNOX?

Is CTSO or NNOX more profitable?

Which has higher valuation & earnings, CTSO or NNOX?

Does the media favor CTSO or NNOX?

Do analysts prefer CTSO or NNOX?

Summary

How does Cytosorbents compare to LENSAR?

Do analysts prefer CTSO or LNSR?

Does the media refer more to CTSO or LNSR?

Do insiders & institutionals have more ownership in CTSO or LNSR?

Which has more risk & volatility, CTSO or LNSR?

Is CTSO or LNSR more profitable?

Which has preferable valuation & earnings, CTSO or LNSR?

Summary

How does Cytosorbents compare to Daxor?

Do analysts rate CTSO or DXR?

Do insiders and institutionals have more ownership in CTSO or DXR?

Which has preferable valuation & earnings, CTSO or DXR?

Is CTSO or DXR more profitable?

Does the media prefer CTSO or DXR?

Which has more risk and volatility, CTSO or DXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools